CervoMed (NASDAQ:CRVO) Upgraded at Jones Trading

Jones Trading upgraded shares of CervoMed (NASDAQ:CRVO) from a hold rating to a buy rating in a report released on Thursday morning,Benzinga reports. They currently have $15.00 target price on the stock.

Several other research analysts also recently commented on the company. Canaccord Genuity Group decreased their price objective on CervoMed from $65.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Brookline Capital Management upgraded CervoMed from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Finally, HC Wainwright downgraded shares of CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, CervoMed has an average rating of “Moderate Buy” and a consensus target price of $25.75.

CervoMed Stock Down 6.2 %

CRVO stock opened at $5.79 on Thursday. The firm’s fifty day moving average is $2.37 and its 200 day moving average is $8.18. CervoMed has a 52 week low of $1.80 and a 52 week high of $26.38.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CRVO. FMR LLC bought a new stake in shares of CervoMed during the third quarter valued at approximately $56,000. Barclays PLC lifted its position in CervoMed by 323.6% during the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after buying an additional 5,919 shares during the period. Virtu Financial LLC bought a new stake in shares of CervoMed during the 4th quarter valued at $26,000. DRW Securities LLC purchased a new stake in shares of CervoMed in the 4th quarter worth about $30,000. Finally, Mariner LLC bought a new position in shares of CervoMed in the 4th quarter worth about $30,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.